| abstract |
The present invention relates to the use of at least one antibody, or a functional fragment thereof, capable of binding to the CD151 protein and thus of inhibiting tumour growth, for the preparation of a medicament for use in the treatment of cancer. The invention also relates to a composition for the treatment of cancer, comprising, as active ingredient, at least one anti-CD151 antibody, or a functional fragment thereof, capable of binding to the CD151 protein and/or of inhibiting the development of primary tumours and/or of inhibiting its metastasis-promoting activity, wherein said antibodies may consist of the TS151 and/or TS151r antibodies. |